Sjogren's Syndrome News

Sjogren's Syndrome	Welcome, Profile Billing Logout

«1 234 5 6 7 8 9 10 11 12 13...145 146 »

||||||||||  ianalumab (VAY736) / Novartis
Trial completion date:  NEPTUNUS-2: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (clinicaltrials.gov) -  Aug 13, 2024
P3, N=505, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2028 --> May 2027

|||||||||| Journal, Heterogeneity: Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sj (Pubmed Central) - Aug 12, 2024
Our research identified distinct stromal and immune cell populations linked to pSS, revealing new potential targets for its management. The activation of myeloid, B, and T cells could contribute to pSS pathogenesis, providing important guidance for therapeutic approaches.

|||||||||| Biomarker, Journal: The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment. (Pubmed Central) - Aug 12, 2024
The diagnostic value of RDW-SD was higher than that of RDW-CV in CTD-ILD patients. NLR, SII, MLR, and PLR have potential value in diagnosing the different types of CTD-ILD.

||||||||||  RD06-04 / Wuhan Union Hospital
New P1 trial:  Clinical Study on Targeted CD19 CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov) -  Aug 12, 2024
P1, N=20, Recruiting,  Sponsor: Nanjing Bioheng Biotech Co., Ltd.

|||||||||| Meet the Professor: Sj (Room 159AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_683;
Meet the Professor sessions offer small-group interactions with highly-esteemed experts in rheumatology, providing attendees the opportunity for in-depth, case-based discussions and personalized insights on cutting-edge topics.SESSION REQUIRES ADDITIONAL REGISTRATION ($). Attendance is capped at 25.Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease

|||||||||| Meet the Professor: Sj (Room 159AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_582;
Meet the Professor sessions offer small-group interactions with highly-esteemed experts in rheumatology, providing attendees the opportunity for in-depth, case-based discussions and personalized insights on cutting-edge topics.SESSION REQUIRES ADDITIONAL REGISTRATION ($). Attendance is capped at 25.Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease

|||||||||| Epithelial (Room 144ABC) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_552;

|||||||||| Where the Rubber Meets the Road: Exploring the Epithelial-Immune Cell Interplay Underlying Sj (Room 144ABC) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_549;
Attendance is capped at 25.Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease Learning Objectives: Identify challenging features in the diagnosis and management of rheumatic disease and how to overcome themDevelop timely individualized evidence-based treatment plans for patients with difficult-to-treat rheumatic disease Sj

|||||||||| Clinical Trial Update in Sj (Room 150AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_483;

|||||||||| Novel Imaging to Diagnose Sj (Room 150AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_482;

|||||||||| Challenges for Disease -Modifying Therapy in Sjogren's Disease (Room 150AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_481;

|||||||||| Novel Imaging and Therapeutics in Sj (Room 150AB) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_480;
Sj Diagnosis and treatment options for Sj

|||||||||| Rheumatology Perspective of Pulmonary and Renal Manifestations of Sj (Room 206) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_327;

|||||||||| Nuts and Bolts of Glandular Pathology in Sj (Room 206) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_326;

|||||||||| Unmet Needs in Sj (Room 206) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_324;
Diagnosis and treatment options for Sj The complication of lymphoma is common in Sj

|||||||||| Clinical Utility of Ultrasound in Sjogren Syndrome and Its Differentials () - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_200;

|||||||||| Sj (Ballroom A) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_179;

|||||||||| Sj (Ballroom A) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_148;

|||||||||| Sj (Ballroom A) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_117;

|||||||||| Sj (Ballroom A) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_86;

|||||||||| Review, Journal: Punctal Cautery in Dry Eye Disease: A Systematic Review. (Pubmed Central) - Aug 11, 2024
The complication of lymphoma is common in Sj Based on non-comparative studies, thermal or surgical punctal occlusion improves tear volume in DED with similar recanalization rates; however, randomized controlled trials are needed to ascertain the real effects of punctal cautery on DED.

|||||||||| iscalimab (CFZ533) / Novartis
P2b data, Journal: Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj (Pubmed Central) - Aug 10, 2024
P2
The study met the primary objective of demonstrating a significant dose-response relationship with iscalimab in terms of disease activity at week 24. Iscalimab was well tolerated and showed initial clinical benefit over placebo in two distinct populations of patients with Sj

|||||||||| hydroxychloroquine / Generic mfg.
Observational data, Journal: The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters. (Pubmed Central) - Aug 9, 2024
HCQ's impact on QTc prolongation is influenced by therapeutic context, coadministered drugs, and patient demographics. The findings underscore the necessity of cautious HCQ use, particularly in acute settings like COVID-19, where monitoring and consideration of drug interactions and patient-specific factors are critical.

|||||||||| Biomarker, New P1 trial: A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sj (clinicaltrials.gov) - Aug 9, 2024
P1, N=132, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.

|||||||||| Rituxan (rituximab) / Roche
Journal: Primary Sj (Pubmed Central) - Aug 9, 2024
The findings underscore the necessity of cautious HCQ use, particularly in acute settings like COVID-19, where monitoring and consideration of drug interactions and patient-specific factors are critical. She was treated with Pilocarpine 5

|||||||||| Journal: Allogenic and autologous nondiluted serum eye drops-validation strategy compliant with good manufacturing practice. (Pubmed Central) - Aug 8, 2024
The GMP compliance of our production, storage and transport processes for autologous and allogenic SEDs was successfully validated. 100% serum eye drops in single-use applicators can be safely used for up to 24?h after opening.

|||||||||| Journal: HLA-DR genotypes in patients with primary Sj (Pubmed Central) - Aug 8, 2024
100% serum eye drops in single-use applicators can be safely used for up to 24?h after opening. In patients with Sj

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
Review, Journal, Checkpoint inhibition: Sjogren's syndrome due to immune checkpoint inhibitors (ICIs): Insights from a single-institution series and systematic review of the literature. (Pubmed Central) - Aug 8, 2024
Caring for patients with ICI-related Sjogren's syndrome is facilitated by a multidisciplinary effort including oncologists, otolaryngologists, dentists, ophthalmologists and rheumatologists. Expanding the knowledge base pertaining to iatrogenic Sjogren's syndrome in patients on ICIs will be helpful in promoting early detection and treatment, and improving outcomes.

|||||||||| Lecture: Salivary Gland Ultrasound in Sjogren's Syndrome () - Aug 8, 2024 - Abstract #APLAR2024APLAR_376;
Sponsored by Canon Medical. Endorsed by the Chapter of Rheumatologists, College of Physicians, Singapore.

|||||||||| Clinical characteristics of patients with Sjogren's syndrome combined with pulmonary arterial hypertension overlapping or not overlapping other connective tissue diseases () - Aug 8, 2024 - Abstract #APLAR2024APLAR_315;

|||||||||| Spatial transcriptomics reveals that CXCL9+ fibroblasts promote the pathogenesis of Sj () - Aug 8, 2024 - Abstract #APLAR2024APLAR_311;

|||||||||| Plasma proteomic biomarkers indicating the severity and progression of interstitial lung disease in primary Sjogren's syndrome () - Aug 8, 2024 - Abstract #APLAR2024APLAR_309;

|||||||||| Linc01150 in CD4+T Cells Promotes Lymphocyte Infiltration in Primary Sjogren's Syndrome by Binding to MiR-1207-5p () - Aug 8, 2024 - Abstract #APLAR2024APLAR_301;

|||||||||| Journal: Association between geniquin therapy and the risk of developing periodontal disease in patients with primary Sj (Pubmed Central) - Aug 7, 2024
The adjusted HR for PD treatment was 1.843. Patients diagnosed with pSS showed an increased risk of developing subsequent PD and receiving PD treatment than patients without pSS, while pSS patients receiving geniquin therapy showed even higher risks.

|||||||||| Rituxan (rituximab) / Roche
Journal: Shrinking Lung Syndrome: A Rare Pulmonary Complication of Systemic Lupus Erythematosus. (Pubmed Central) - Aug 7, 2024
A 38-year-old female recently diagnosed with SLE on hydroxychloroquine, prednisone, and methotrexate presented with a one-week history of progressive shortness of breath, non-productive cough, and pleuritic chest pain...Initial treatment included broad-spectrum antibiotics and intravenous methylprednisolone for a suspected lupus flare...Treatment often includes corticosteroids such as methylprednisolone and immunosuppressive agents. Rituximab has shown improvement in cases unresponsive to conventional therapy.

|||||||||| Review, Journal: Ischemic stroke or transient ischemic attack due to cervical and intracranial large-vessel vasculitis secondary to primary Sj (Pubmed Central) - Aug 7, 2024
Cerebral infarctions were characterized by recurrence and watershed pattern. Magnetic resonance vessel wall imaging (MR-VWI) helps to identify the inflammatory pathology of large vessel lesion in PSS.

|||||||||| Journal: Performance of salivary glands ultrasonography, shear wave elastography and their combined use for the diagnosis of primary and secondary Sj (Pubmed Central) - Aug 6, 2024
Magnetic resonance vessel wall imaging (MR-VWI) helps to identify the inflammatory pathology of large vessel lesion in PSS. SGUS and SWE are pivotal in the diagnosis of Sj

|||||||||| Clinical, Journal, Biopsy: Surgical advantage of modified labial salivary gland biopsy using chalazion forceps: a prospective randomized controlled study. (Pubmed Central) - Aug 6, 2024
The positive biopsy results in the different surgical-method groups were consistent with the expert opinions and the 2016 ACR-EULAR primary SS classification criteria. The modified LSGB using an auxiliary chalazion forceps offers a good safety with a small incision, shorter operative time, less bleeding, reduced pain and a low incidence of postoperative complications.The match rate of LSGB pathological results of the proposed surgical procedure with the final diagnosis of pSS is high.

|||||||||| Journal: Corneal Epithelial Thickness in Sjogren's Disease: A Pilot Study. (Pubmed Central) - Aug 6, 2024
There was a significant correlation between variability of corneal epithelial thickness and decreased tear production in Sjogren's patients. Further larger studies are needed to understand the relationship of CET with objective and subjective measurements of ocular surface disease.

|||||||||| Journal, Causal relationship: The causal relationship between autoimmune diseases and rhinosinusitis, and the mediating role of inflammatory proteins: a Mendelian randomization study. (Pubmed Central) - Aug 6, 2024
Subsequent analyses identified interleukin-10 (IL-10) as a potential mediator for the association of MS, RA and HT with CRS, respectively., while C-X-C motif chemokine 10 levels (CXCL10) and T-cell surface glycoprotein CD6 isoform levels (CD6) were found to influence HT's effect on CRS. Our findings demonstrate a causative link between specific autoimmune diseases and rhinosinusitis, highlighting IL-10, CXCL10, and CD6 as potential mediators in this association.

|||||||||| Journal: Sj (Pubmed Central) - Aug 6, 2024
Our MR study supports a potential causal association between SS and a reduced risk of PD. Further extensive clinical investigations and comprehensive fundamental research are warranted to elucidate the underlying mechanisms linking SS and PD.

|||||||||| Journal: Self-immunological disease aid diagnosis with ConvSANet and Eu-clidean distance. (Pubmed Central) - Aug 6, 2024
The research demonstrated that the 2D spectrogram created with ED closely resembles the original 1D spectral data. This indicates that ED effectively captures key features and important information from the original data, providing a strong descript.

|||||||||| Journal: Overlap of Sarcoidosis and Sj (Pubmed Central) - Aug 5, 2024
This indicates that ED effectively captures key features and important information from the original data, providing a strong descript. No abstract available

|||||||||| Vismed (sodium hyaluronate) / TRB Chemedica
Journal: A randomised study comparing performance and safety of Eyestil Plus (Pubmed Central) - Aug 3, 2024
No abstract available This clinical investigation showed the non-inferiority of Eyestil Plus

|||||||||| Journal: Hypokalemic quadriplegia in Sjogren's syndrome: A case report. (Pubmed Central) - Aug 2, 2024
Therefore, clinicians should maintain a high index of suspicion for this condition in patients presenting with muscle weakness. Prompt and precise history takingand screening, and initiating appropriate management to prevent adverse outcomes.

|||||||||| New trial: Functional Analysis of Salivary Glands and Correlation With Sialoscintigraphy in Sjogren's Syndrome (clinicaltrials.gov) - Aug 2, 2024
P=N/A, N=60, Recruiting, Sponsor: National Taiwan University Hospital

|||||||||| Biomarker, Journal, Pan tumor: ANA-arthritis: clinical and biomarker characterization of a population for basket trials. (Pubmed Central) - Aug 1, 2024
Prompt and precise history takingand screening, and initiating appropriate management to prevent adverse outcomes. We define ANA-Arthritis, a more clinically and immunologically homogeneous population than existing RMDs for trials, and a more prevalent population for therapies in the clinic.

|||||||||| Review, Journal: Evaluation of stem cell therapies in companion animal disease models: A concise review (2015-2023). (Pubmed Central) - Aug 1, 2024
Enhanced understanding of the temporal course of disease processes using advanced -omics approaches may further inform mechanisms of action and help define appropriate timing of interventions. Future directions of stem cell-based therapies could include use of stem-cell derived extracellular vesicles, or cell conditioning approaches to direct cells to specific pathways that are tailored to individual disease processes and stages of illness.

|||||||||| PLEURO-PARENCHYMAL FIBROELASTOSIS IN THE SETTING OF SJOGREN'S SYNDROME (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5370;

|||||||||| COVID-19 COINFECTION WITH RECURRENT MYCOBACTERIUM ABSCESSUS IN PATIENT WITH SJOGREN SYNDROME (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5184;



	Diseases Companies Products Productz Mechanisms of Action Sites